1+ hour, 23+ min ago  (227+ words) The Pharma Letter Key findings of STADA Health Report 2026 In 2026, the STADA Health Report captures Europe's healthcare landscape shaped by colliding forces: Healthcare systems under sustained pressure, a population empowered to take their health into their own hands, and the…...

7+ hour, 34+ min ago  (270+ words) The Pharma Letter Astex strikes cancer collaboration with Genentech UK drugmaker Astex Pharmaceuticals today announced that it has entered into an exclusive, worldwide research collaboration and license agreement with Genentech, a Roche (ROG: SIX) subsidiary, to identify small molecule drug…...

3+ day, 2+ hour ago  (251+ words) The Pharma Letter - Drugmakers call on Russian state to speed new drugs registration Russian pharmaceutical companies and global drugmakers operating in the local market have called on the national government to speed the process of entering new drugs in public…...

3+ day, 3+ hour ago  (246+ words) The Pharma Letter - Scribe Therapeutics files for a $75 million IPO Scribe Therapeutics, a Phase I biotech developing CRISPR therapies for cardiovascular diseases, filed on Thursday with the Securities & Exchange Commission (SEC) to raise up to $75 million in an initial public…...

3+ day, 7+ hour ago  (220+ words) The Pharma Letter - Angitia reshapes bone pipeline after ending Phase III trial Angitia Biopharmaceuticals has terminated a Phase III trial of AGA111, its most advanced clinical-stage asset, about five months after raising $130 million in series D financing. The privately-held bone disease…...

5+ day, 1+ hour ago  (276+ words) The Pharma Letter - The Pharma Letter M&A round-up - June 2026 The Pharma Letter's June M&A coverage showed that biopharma buyers remain prepared to pay heavily for late-stage or strategically useful assets, while also using smaller deals to fill technology…...

5+ day, 7+ hour ago  (242+ words) The Pharma Letter - Abivax expands obefazimod safety data ahead of FDA filing Abivax (Euronext Paris) has reported additional Phase III data for investigational ulcerative colitis therapy obefazimod, saying the expanded dataset strengthens confidence in the oral medicine's long-term safety profile…...

5+ day, 19+ hour ago  (216+ words) The Pharma Letter - Exonate names Olav Helleb" CEO as EXN407 moves toward Phase IIb UK biotech company Exonate has appointed Olav Helleb" as chief executive, as it prepares to start a Phase IIb trial of its lead diabetic eye disease candidate…...

6+ day, 2+ hour ago  (225+ words) The Pharma Letter - Novartis debuts radioligand therapy for prostate cancer in India Swiss pharma giant Novartis (NOVN: VX) has launched India's first radioligand therapy for advanced prostate cancer, marking a significant milestone in precision oncology. The therapy, Pluvicto (lutetium-177 vipivotide tetraxetan),…...

1+ week, 4+ hour ago  (229+ words) The Pharma Letter - Replimune gets FDA review for melanoma drug after prior setbacks Replimune (Nasdaq: REPL) has gained another chance to secure accelerated approval for its lead melanoma candidate RP1, after the US Food and Drug Administration accepted a resubmitted biologics…...